16 September 2026 editorial review · Item
AT247 ultra-rapid insulin: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: AT247 ultra-rapid insulin
Scope and findings:
- Read primary2025 interim slides: AT247 Phase1 completed, in-vitro AID modeling. Current portfolio focuses on AT278; absence of AT247 is not evidence of discontinuation. No fresh AT247 clinical start, phase 3 or approval established; detailed2022 PK claims not reread.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.